Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 303-317
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.303
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.303
Table 1 Baseline demographics
| Characteristic | N = 431 | n/N (missing %) |
| Age (yr) | 65 (60, 75) | 43 / 43 (0%) |
| Sex | 43 / 43 (0%) | |
| Female | 13 (30%) | |
| Male | 30 (70%) | |
| Stage | 43 / 43 (0%) | |
| I | 11 (26%) | |
| II | 10 (23%) | |
| III | 8 (19%) | |
| IV | 14 (33%) | |
| Grade | 43 / 43 (0%) | |
| G1 | 1 (2.3%) | |
| G2 | 10 (23%) | |
| G3 | 31 (72%) | |
| Gx | 1 (2.3%) | |
| Tumour location | 43 / 43 (0%) | |
| Distal | 14 (33%) | |
| Proximal | 26 (60%) | |
| Whole stomach | 3 (7.0%) | |
| Lauren classification | 41 / 43 (4.7%) | |
| Diffuse | 26 (63%) | |
| Intestinal | 13 (32%) | |
| Mixed | 2 (4.9%) | |
| Signet ring cell (present) | 26 (63%) | 41 / 43 (4.7%) |
| H. pylori history | 32 / 43 (26%) | |
| Negative | 22 (69%) | |
| Positive | 9 (28%) | |
| Treated | 1 (3.1%) | |
| Smoker | 40 / 43 (7.0%) | |
| Yes | 9 (22%) | |
| No | 14 (35%) | |
| Ex | 17 (42%) | |
| Smoker (pack years) | 7 (0, 32) | 39 / 43 (9.3%) |
| Surgery | 43 / 43 (0%) | |
| Total gastrectomy | 20 (47%) | |
| Distal gastrectomy | 14 (33%) | |
| No resection | 9 (21%) | |
| Neoadjuvant chemotherapy | 18 (42%) | 43 / 43 (0%) |
| CD4/CD8 ratio (% positive) | 1.7 (1.2, 2.8) | 42 / 43 (2.3%) |
| CD4 (% positive) | 14 (7, 24) | 43 / 43 (0%) |
| CD8 (% positive) | 8 (5, 11) | 42 / 43 (2.3%) |
| Galectin-3 (% positive) | 46 (30, 57) | 43 / 43 (0%) |
| E-cadherin (% positive) | 18 (6, 28) | 43 / 43 (0%) |
| E-cadherin H-score | 22 (7, 40) | 43 / 43 (0%) |
Table 2 Clinicopathologic factors according to treatment response
| Characteristic | Incomplete response, N = 141 | Response, N = 41 | P value2 |
| Age (yr) | 60 (57, 63) | 60 (52, 67) | > 0.9 |
| Sex | 0.3 | ||
| F | 5 (36%) | 0 (0%) | |
| M | 9 (64%) | 4 (100%) | |
| Stage | 0.6 | ||
| I | 2 (14%) | 2 (50%) | |
| II | 5 (36%) | 1 (25%) | |
| III | 6 (43%) | 1 (25%) | |
| IV | 1 (7.1%) | 0 (0%) | |
| Grade | 0.6 | ||
| G1 | 1 (7.1%) | 0 (0%) | |
| G2 | 2 (14%) | 2 (50%) | |
| G3 | 10 (71%) | 2 (50%) | |
| Gx | 1 (7.1%) | 0 (0%) | |
| Tumour location | > 0.9 | ||
| Distal | 3 (21%) | 1 (25%) | |
| Proximal | 10 (71%) | 3 (75%) | |
| Whole stomach | 1 (7.1%) | 0 (0%) | |
| Lauren classification | 0.5 | ||
| Diffuse | 10 (71%) | 1 (33%) | |
| Intestinal | 4 (29%) | 2 (67%) | |
| Signet ring cell (present) | 9 (64%) | 1 (33%) | 0.5 |
| H. pylori history | > 0.9 | ||
| Negative | 8 (57%) | 2 (50%) | |
| Positive | 3 (21%) | 1 (25%) | |
| Unknown | 3 (21%) | 1 (25%) | |
| Smoker | > 0.9 | ||
| Yes | 4 (33%) | 2 (50%) | |
| No | 4 (33%) | 1 (25%) | |
| Ex | 4 (33%) | 1 (25%) | |
| Smoker (pack years) | 13 (0, 40) | 36 (25, 42) | 0.5 |
| Surgery | > 0.9 | ||
| Total gastrectomy | 10 (71%) | 3 (75%) | |
| Distal gastrectomy | 3 (21%) | 1 (25%) | |
| No resection | 1 (7.1%) | 0 (0%) |
- Citation: Skubleny D, Lin A, Garg S, McLean R, McCall M, Ghosh S, Spratlin JL, Schiller D, Rayat G. Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. World J Gastrointest Oncol 2023; 15(2): 303-317
- URL: https://www.wjgnet.com/1948-5204/full/v15/i2/303.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i2.303